Intensity Therapeutics presents updated INT230-6 data: Phase 3 sarcoma trial planned; tumor necrosis in breast cancer

INTENSITY THERAPEUTICS, INC.

INT230-6 induced up to 95% tumor necrosis in presurgical breast cancer after 1-2 injections; safety profile favorable.
Phase 3 soft tissue sarcoma trial designed; median OS not reached vs synthetic control median of 205 days.
Phase 1/2 IT-01 study in 110 patients with 25 tumor types completed; database locked; data presented at ASCO and SITC.
Phase 2/3 breast cancer study designed; data expected Q4 2023; accelerated approval path via pCR discussed with FDA.
Company to present at H.C. Wainwright conference on Sept 11, 2023; one-on-one meetings available.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.